Sage Therapeutics 관리

관리 기준 확인 1/4

Sage Therapeutics CEO는 Barry Greene, Dec2020 에 임명되었습니다 의 임기는 3.92 년입니다. 총 연간 보상은 $ 6.24M, 12.8% 로 구성됩니다. 12.8% 급여 및 87.2% 보너스(회사 주식 및 옵션 포함). 는 € 439.73K 가치에 해당하는 회사 주식의 0.14% 직접 소유합니다. 439.73K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 9.3 년입니다.

주요 정보

Barry Greene

최고 경영자

US$6.2m

총 보상

CEO 급여 비율	12.8%
CEO 임기	3.9yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	9.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Barry Greene 의 보수는 Sage Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$338m
Jun 30 2024	n/a	n/a	-US$446m
Mar 31 2024	n/a	n/a	-US$503m
Dec 31 2023	US$6m	US$799k	-US$541m
Sep 30 2023	n/a	n/a	-US$656m
Jun 30 2023	n/a	n/a	-US$592m
Mar 31 2023	n/a	n/a	-US$558m
Dec 31 2022	US$6m	US$761k	-US$533m
Sep 30 2022	n/a	n/a	-US$510m
Jun 30 2022	n/a	n/a	-US$503m
Mar 31 2022	n/a	n/a	-US$484m
Dec 31 2021	US$59m	US$735k	-US$458m
Sep 30 2021	n/a	n/a	US$642m
Jun 30 2021	n/a	n/a	US$666m
Mar 31 2021	n/a	n/a	US$637m
Dec 31 2020	US$836k	US$53k	US$606m

보상 대 시장: Barry 의 총 보상 ($USD 6.24M )은 German 시장( $USD 1.03M ).

보상과 수익: 회사가 수익성이 없는 동안 Barry 의 보상이 증가했습니다.

CEO

Barry Greene (61 yo)

3.9yrs

테뉴어

US$6,237,491

보상

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

리더십 팀

이름	위치	테뉴어	보상	소유권
Barry Greene	President	3.9yrs	US$6.24m	0.14% € 439.7k
Christopher Benecchi	Chief Operating Officer	no data	US$2.28m	0.0081% € 25.8k
Laura Gault	Chief Medical Officer	2.1yrs	US$1.27m	0.018% € 55.5k
Mike Quirk	Chief Scientific Officer	1.3yrs	데이터 없음	데이터 없음
Ashley Kaplowitz	Director of Investor Relations	no data	데이터 없음	데이터 없음
Gregory Shiferman	Senior VP & General Counsel	no data	데이터 없음	데이터 없음
Pamela Herbster	VP & Head of People	less than a year	데이터 없음	데이터 없음
Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance	no data	데이터 없음	데이터 없음
Vanessa Procter	Senior Vice President of Corporate Affairs	3yrs	데이터 없음	데이터 없음
Aaron Koenig	Medical Director of Early Clinical Development	no data	데이터 없음	데이터 없음
Maren Killackey	Senior Analyst of Investor Relation	no data	데이터 없음	데이터 없음
Jeff Boyle	Investor Contact	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SG7 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Barry Greene	President	4.1yrs	US$6.24m	0.14% € 439.7k
Michael Cola	Independent Director	10.2yrs	US$440.05k	0% € 0
James Frates	Independent Director	10.5yrs	US$435.05k	0.0046% € 14.7k
David Farb	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Geno Germano	Independent Chair of the Board	8.3yrs	US$417.55k	0% € 0
Michael Rogawski	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
James Audia	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Christine Marx	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
A. Morrow	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Stephen Moss	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Scott Runyon	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Donald Stein	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

9.3yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: SG7 의 이사회는 경험(평균 재직 기간 9.3 년)으로 간주됩니다.

Sage Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

President recently bought €492k worth of stock

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.70 loss per share (vs US$2.68 loss in 2Q 2023)

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: US$9.05 loss per share (vs US$8.98 loss in FY 2022)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022)

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Share price stability

First quarter 2023 earnings released: US$2.46 loss per share (vs US$2.07 loss in 1Q 2022)

Full year 2022 earnings released: US$8.98 loss per share (vs US$7.81 loss in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought €492k worth of stock

Third quarter 2022 earnings released: US$2.31 loss per share (vs US$2.21 loss in 3Q 2021)

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.83 loss in 2Q 2021)

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Insider recently bought €239k worth of stock

First quarter 2022 earnings released: US$2.07 loss per share (vs US$1.64 loss in 1Q 2021)

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Sage Therapeutics, Inc. Provides Business Update

Investor sentiment deteriorated over the past week

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)

President recently bought €861k worth of stock

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €825k worth of stock

Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Investor sentiment improved over the past week

Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth

First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020)

Chief Operating Officer has left the company

Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021

Investor sentiment deteriorated over the past week

Revenue beats expectations